Table 4.
The logistic analysis of rs11871753
| Mutation a | B | SEM | Wald | df | p value | Exp (B) | 95% CI | |
|---|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||||
| Control | ||||||||
| Intercept | 48.435 | 4611.289 | 0.000 | 1 | 0.992 | |||
| Size ≤2 cm | −16.684 | 0.895 | 347.625 | 1 | 0.000 | 5.681E‐8 | 9.835E‐9 | 3.282E‐7 |
| Size 2–5 cm | −1.388 | 0.924 | 2.256 | 1 | 0.133 | 0.250 | 0.041 | 1.527 |
| Size >5 cm | −.047 | 1.183 | 0.002 | 1 | 0.968 | 0.954 | 0.094 | 9.701 |
| Unknown | 0 b | — | — | 0 | — | — | — | — |
| With lymph node | 1.110 | 0.594 | 3.491 | 1 | 0.062 | 3.035 | 0.947 | 9.728 |
| Without lymph node | 0 b | — | — | 0 | — | — | — | — |
| Carcinoma in situ | 1.836 | 1.915 | 0.919 | 1 | 0.338 | 6.272 | 0.147 | 267.766 |
| Invasive nonspecific cancer | 1.516 | 1.496 | 1.027 | 1 | 0.311 | 4.555 | 0.243 | 85.539 |
| Invasive specific cancer | −1.027 | 2.155 | 0.227 | 1 | 0.634 | 0.358 | 0.005 | 24.478 |
| Other | 0 b | — | — | 0 | — | — | — | — |
| Lymph metastasis=0 | −17.182 | 2427.652 | 0.000 | 1 | 0.994 | 3.451E‐8 | 0.000 | — c |
| Lymph metastasis 1–3 | −17.858 | 2427.652 | 0.000 | 1 | 0.994 | 1.755E‐8 | 0.000 | — c |
| Lymph metastasis>3 | −17.979 | 2427.652 | 0.000 | 1 | 0.994 | 1.555E‐8 | 0.000 | — c |
| Lymph metastasis unknown | 0 b | — | — | 0 | — | — | — | — |
| T = 1 | 15.744 | 0.000 | — | 1 | — | 6881668.767 | 6881668.767 | 6881668.767 |
| T = 2 | 0 b | — | — | 0 | — | — | — | — |
| T = 3 | 0 b | — | — | 0 | — | — | — | — |
| T unknown | 0 b | — | — | 0 | — | — | — | — |
| N = 0 | −.988 | 0.000 | — | 1 | — | 0.372 | 0.372 | 0.372 |
| N = 1 | 0 b | — | — | 0 | — | — | — | — |
| M = 0 | −.371 | 1.577 | 0.055 | 1 | 0.814 | 0.690 | 0.031 | 15.182 |
| M = 1 | 0 b | — | — | 0 | — | — | — | — |
| ER negative | 29.045 | 1976.039 | 0.000 | 1 | 0.988 | 4110700766525.211 | 0.000 | — c |
| ER positive | 0 b | — | — | 0 | — | — | — | — |
| PR negative | −15.403 | 1386.464 | 0.000 | 1 | 0.991 | 2.045E‐7 | 0.000 | — c |
| PR positive | 0 b | — | — | 0 | — | — | — | — |
| HER2 negative | .857 | 2.032 | 0.178 | 1 | 0.673 | 2.356 | 0.044 | 126.326 |
| HER2 positive | 1.563 | 2.196 | 0.507 | 1 | 0.477 | 4.773 | 0.065 | 352.898 |
| HER2 unknown | 0 b | — | — | 0 | — | — | — | — |
| ki67 ≤30% | −15.680 | 3667.180 | 0.000 | 1 | 0.997 | 1.549E‐7 | 0.000 | — c |
| ki67 >30% | −15.744 | 3667.180 | 0.000 | 1 | 0.997 | 1.453E‐7 | 0.000 | — c |
| ki67 unknown | 0 b | — | — | 0 | — | — | — | — |
| luminalA | −15.960 | 1386.464 | 0.000 | 1 | 0.991 | 1.171E‐7 | 0.000 | — c |
| luminalB | −15.832 | 1386.464 | 0.000 | 1 | 0.991 | 1.331E‐7 | 0.000 | — c |
| HER2 | −30.331 | 1976.040 | 0.000 | 1 | 0.988 | 6.723E‐14 | 0.000 | — c |
| TNBC | −29.095 | 1976.040 | 0.000 | 1 | 0.988 | 2.313E‐13 | 0.000 | — c |
| Other | 0 b | — | — | 0 | — | — | — | — |
Abbreviations: ER, estrogen receptor; HER2, ER‐, PR‐, HER2+; Ki67, antigen identified by monoclonal antibody ki67, a protein which in humans is encoded by the MKI67 gene; luminalA, ER+, PR+, HER2‐, ki67<30%; luminalB, ER+, PR+, HER2‐, KI67>30%; PR, progesterone receptor; SEM, standard error of mean; TNBC: triple‐negative breast cancer, ER‐, PR‐, HER2‐.
a
^1.
b
Set to zero.
c
Floating point overflow, set to system missing values.